|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.4 TWD | -1.97% |
|
+3.88% | 0.00% |
| 04-19 | InnoPharmax Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | InnoPharmax Inc. Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
InnoPharmax Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was TWD 29.13 million compared to TWD 48.06 million a year ago. Net loss was TWD 103.18 million compared to TWD 92.97 million a year ago.
Basic loss per share from continuing operations was TWD 1.19 compared to TWD 1.08 a year ago. Diluted loss per share from continuing operations was TWD 1.19 compared to TWD 1.08 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 50.81M | |
| +20.78% | 43.29B | |
| +27.64% | 22.38B | |
| +19.03% | 15.51B | |
| +18.68% | 14.52B | |
| +54.64% | 12.93B | |
| -0.05% | 6.79B | |
| -11.39% | 6.56B | |
| +17.73% | 5.87B | |
| -8.87% | 5.73B |
INNOPHARMAX INC. 
